GlaxoSmithKline

A settlement has been reached in the class action lawsuit filed against GlaxoSmithKline, the manufacturer of the discontinued Lymerix Lyme disease vaccine. The suit alleged the vaccine could cause an arthritic condition in some people. According to the judge's ruling, "This lawsuit had two primary purposes at its inception: to warn patients of the drug's potential dangers, and to provide funds to plaintiffs for ongoing medical monitoring. The first goal is met by removal of the drug from the market; the second was not pursued because it was deemed unnecessary." (Jul-09-03) [KANSAS CITY STAR]